1-benzyl 2-ethyl(2S,4S)-4-(phenylselanyl)pyrrolidine-1,2-dicarboxylate | 84062-29-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-benzyl 2-ethyl(2S,4S)-4-(phenylselanyl)pyrrolidine-1,2-dicarboxylate
• 英文别名: (2S,4S)-N-benzyloxycarbonyl-4-phenylselenoproline ethyl ester；Ethyl N-Cbz-4-cis-(phenylselenenyl)-L-prolinate；1-benzyl 2-ethyl (2S,4S)-4-(phenylselanyl)pyrrolidine-1,2-dicarboxylate；1-O-benzyl 2-O-ethyl (2S,4S)-4-phenylselanylpyrrolidine-1,2-dicarboxylate
• CAS: 84062-29-3
• 化学式: C₂₁H₂₃NO₄Se
• 分子量: 432.378
• InChiKey: GBGHOWNPXOQDNM-OALUTQOASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.78
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-benzyl 2-ethyl(2S,4S)-4-(phenylselanyl)pyrrolidine-1,2-dicarboxylate 在 palladium on activated charcoal N-甲基吗啉 、 吡啶 、 lithium hydroxide 、 四丁基氟化铵 、 氢气 、 双氧水 、 双(2-氧代-3-恶唑烷基)次磷酰氯 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， -15.0~25.0 ℃ 、275.79 kPa 条件下， 反应 41.0h， 生成 Cyclo<(N-L-prolyl-N-methyl-D-leucyl)-O-<oxy>-3-oxo-2,5-dimethylhexanoyl>-L-leucyl>-L-prolyl-N,O-dimethyl-L-tyrosyl>-L-threonyl>
  参考文献：
  名称：

  Synthesis of New Didemnin B Analogs for Investigations of Structure/Biological Activity Relationships

  摘要：

  Modifications were introduced in the side chain of didemnin B to afford several analogs (1f-1j) for biological testing in order to identify the features responsible for the bioactivity of the natural products (1a-1c). To achieve our goal, two changes were made in the proline ring of the beta-turn side chain. Initially, a hydroxyl group was incorporated at the C-4 position of the ring to increase the polar nature of the molecule. Secondly, unsaturation was introduced at C-3 and C-4 to increase the rigidity of the ring and to provide a site for tritiation to follow the drug pathway in biological systems. Improvements were also introduced in the macrocycle construction to produce gram quantities of this unit (1d) for the preparation of the planned analogs. The linear precursor to the macrocycle was oxidized more effectively with 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess-Martin periodinane reagent), and cyclization yields were increased substantially by using a new coupling reagent, pentafluorophenyl diphenylphosphinate (FDPP). (1H-1,2,3-benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and pentafluorophenyl trifluoroacetate were also used to improve other coupling reactions.

  DOI：

  10.1021/jo00097a022
• 作为产物：
  描述：

  (4R)-4-羟基-L-脯氨酸盐酸盐 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 12.5h， 生成 1-benzyl 2-ethyl(2S,4S)-4-(phenylselanyl)pyrrolidine-1,2-dicarboxylate
  参考文献：
  名称：

  [EN] SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
  [FR] COMPOSÉS DE SULFONAMIDE HÉTÉROCYCLIQUES SUBSTITUÉS UTILES COMME MODULATEURS DE TRPA1

  摘要：

  本发明涉及式I或II的化合物及其盐。此外，本发明还涉及制备这些化合物的方法以及使用这些化合物的方法，以及含有这些化合物的药物组合物。这些化合物可能对治疗由TRPA1介导的疾病和状况，如疼痛，具有用途。

  公开号：

  WO2015052264A1

文献信息

• HIV protease inhibitors
  申请人：Wong Chi-Huey

  公开号：US06900238B1

  公开（公告）日：2005-05-31

  Combinatorial libraries of HIV and FIV protease inhibitors are characterized by α-keto amide or hydroxyethylamine core structures flanked by on one side by substituted pyrrolidines, piperidines, or azasugars and on the other side by phenylalanine, tyrosine, or substituted tyrosines. The libraries are synthesized via a one step coupling reaction. Highly efficacious drug candidates are identified by screening the libraries for binding and inhibitory activity against both HIV and FIV protease. Drug candidates displaying clinically useful activity against both HIV and FIV protease are identified as being potentially resistive against a loss of inhibitory activity due to development of resistant strains of HIV.

  HIV和FIV蛋白酶抑制剂的组合库以α-酮酰胺或羟乙基胺核心结构为特征，一侧为取代吡咯烷、哌啶或氮代糖，另一侧为苯丙氨酸、酪氨酸或取代酪氨酸。这些库是通过一步偶联反应合成的。通过筛选这些库，识别出对HIV和FIV蛋白酶的结合和抑制活性高效的药物候选化合物。对HIV和FIV蛋白酶都显示出临床有用活性的药物候选化合物被确定为潜在对抗由于HIV耐药株的发展而导致的抑制活性丧失。
• The preparation of (<i>S</i>)-3,4-dehydroproline from (2<i>S</i>,4<i>R</i>)-4-hydroxyproline
  作者：Heinrich Rüeger、M. H. Benn

  DOI：10.1139/v82-419

  日期：1982.12.1

  (2S,4R)-N-Benzyloxycarbonyl-4-tosyloxyproline methyl ester, readily prepared from commercially available (2S,4R)-N-benzyl-oxycarbonyl-4-hydroxyproline, was converted to (S)-3,4-dehydroproline of high enantiomeric purity by a process which involved a highly regioselective phenylselenoxide elimination to introduce the olefinic function.

  (2S,4R)-N-苄氧羰基-4-对甲苯磺酸酯基脯氨酸甲酯，是由商业上可获得的(2S,4R)-N-苄氧羰基-4-羟基脯氨酸制备而成的，通过高度区域选择性的苯基硒氧化物消除反应，引入烯烃功能，将其转化为高对映纯度的(S)-3,4-去氢脯氨酸。
• SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
  申请人：Genentech, Inc.

  公开号：US20160221945A1

  公开（公告）日：2016-08-04

  The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  本发明涉及公式I或II的化合物及其盐。此外，本发明还涉及制造和使用公式I或II化合物的方法，以及包含这些化合物的制药组合物。这些化合物可能有用于治疗由TRPA1介导的疾病和病况，如疼痛。
• Synthesis of New Didemnin B Analogs for Investigations of Structure/Biological Activity Relationships
  作者：Scott C. Mayer、Joshi Ramanjulu、Matthew D. Vera、Amy J. Pfizenmayer、Madeleine M. Joullie

  DOI：10.1021/jo00097a022

  日期：1994.9

  Modifications were introduced in the side chain of didemnin B to afford several analogs (1f-1j) for biological testing in order to identify the features responsible for the bioactivity of the natural products (1a-1c). To achieve our goal, two changes were made in the proline ring of the beta-turn side chain. Initially, a hydroxyl group was incorporated at the C-4 position of the ring to increase the polar nature of the molecule. Secondly, unsaturation was introduced at C-3 and C-4 to increase the rigidity of the ring and to provide a site for tritiation to follow the drug pathway in biological systems. Improvements were also introduced in the macrocycle construction to produce gram quantities of this unit (1d) for the preparation of the planned analogs. The linear precursor to the macrocycle was oxidized more effectively with 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess-Martin periodinane reagent), and cyclization yields were increased substantially by using a new coupling reagent, pentafluorophenyl diphenylphosphinate (FDPP). (1H-1,2,3-benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and pentafluorophenyl trifluoroacetate were also used to improve other coupling reactions.
• [EN] SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS<br/>[FR] COMPOSÉS DE SULFONAMIDE HÉTÉROCYCLIQUES SUBSTITUÉS UTILES COMME MODULATEURS DE TRPA1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015052264A1

  公开（公告）日：2015-04-16

  The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

  本发明涉及式I或II的化合物及其盐。此外，本发明还涉及制备这些化合物的方法以及使用这些化合物的方法，以及含有这些化合物的药物组合物。这些化合物可能对治疗由TRPA1介导的疾病和状况，如疼痛，具有用途。